KR102118565B1 - 하이브리드 경쇄 마우스 - Google Patents

하이브리드 경쇄 마우스 Download PDF

Info

Publication number
KR102118565B1
KR102118565B1 KR1020197012527A KR20197012527A KR102118565B1 KR 102118565 B1 KR102118565 B1 KR 102118565B1 KR 1020197012527 A KR1020197012527 A KR 1020197012527A KR 20197012527 A KR20197012527 A KR 20197012527A KR 102118565 B1 KR102118565 B1 KR 102118565B1
Authority
KR
South Korea
Prior art keywords
human
mouse
light chain
gene
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197012527A
Other languages
English (en)
Korean (ko)
Other versions
KR20190049932A (ko
Inventor
린 맥도날드
션 스티븐스
케이건 규레르
앤드류 제이. 머피
캐롤리나 에이. 호시아와
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20190049932A publication Critical patent/KR20190049932A/ko
Application granted granted Critical
Publication of KR102118565B1 publication Critical patent/KR102118565B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
KR1020197012527A 2010-06-22 2011-06-22 하이브리드 경쇄 마우스 Active KR102118565B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
US61/357,314 2010-06-22
US61/357,317 2010-06-22
PCT/US2011/041370 WO2011163314A1 (en) 2010-06-22 2011-06-22 Hybrid light chain mice

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036183A Division KR101975884B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015360A Division KR102193823B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Publications (2)

Publication Number Publication Date
KR20190049932A KR20190049932A (ko) 2019-05-09
KR102118565B1 true KR102118565B1 (ko) 2020-06-03

Family

ID=44509861

Family Applications (16)

Application Number Title Priority Date Filing Date
KR1020197012527A Active KR102118565B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197017074A Active KR102059909B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020227037565A Pending KR20220150430A (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197002903A Active KR102001430B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020217017823A Active KR102462042B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207036106A Active KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020187036167A Active KR101970944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197037332A Active KR102211911B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207015360A Active KR102193823B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217034867A Active KR102506001B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217002982A Active KR102266097B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001582A Active KR101934852B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197002870A Active KR101991234B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001586A Active KR101945352B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020187036183A Active KR101975884B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020237006658A Pending KR20230036157A (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Family Applications After (15)

Application Number Title Priority Date Filing Date
KR1020197017074A Active KR102059909B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020227037565A Pending KR20220150430A (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020197002903A Active KR102001430B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020217017823A Active KR102462042B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207036106A Active KR102320944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020187036167A Active KR101970944B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197037332A Active KR102211911B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020207015360A Active KR102193823B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217034867A Active KR102506001B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020217002982A Active KR102266097B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001582A Active KR101934852B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020197002870A Active KR101991234B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020137001586A Active KR101945352B1 (ko) 2010-06-22 2011-06-22 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR1020187036183A Active KR101975884B1 (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스
KR1020237006658A Pending KR20230036157A (ko) 2010-06-22 2011-06-22 하이브리드 경쇄 마우스

Country Status (30)

Country Link
US (22) US9012717B2 (enExample)
EP (7) EP2905338B8 (enExample)
JP (17) JP6009441B2 (enExample)
KR (16) KR102118565B1 (enExample)
CN (4) CN103068993B (enExample)
AU (1) AU2011271046B2 (enExample)
BR (3) BR122020013427B1 (enExample)
CA (2) CA2803864C (enExample)
CY (5) CY1117537T1 (enExample)
DK (5) DK2568049T3 (enExample)
ES (5) ES2646052T3 (enExample)
HR (5) HRP20160794T1 (enExample)
HU (5) HUE029692T2 (enExample)
IL (12) IL300712B2 (enExample)
LT (4) LT2905338T (enExample)
ME (5) ME03386B (enExample)
MX (6) MX347322B (enExample)
MY (6) MY195217A (enExample)
NO (1) NO2905338T3 (enExample)
NZ (6) NZ605751A (enExample)
PL (5) PL2568049T3 (enExample)
PT (5) PT2905338T (enExample)
RS (5) RS58736B1 (enExample)
RU (3) RU2601297C2 (enExample)
SG (4) SG186390A1 (enExample)
SI (5) SI2568049T1 (enExample)
SM (5) SMT201700506T1 (enExample)
TR (1) TR201905992T4 (enExample)
WO (2) WO2011163314A1 (enExample)
ZA (5) ZA201300062B (enExample)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
MY195217A (en) * 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
EP2601298B1 (en) * 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013041845A2 (en) * 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SMT201900296T1 (it) 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
HUE061977T2 (hu) * 2013-03-13 2023-09-28 Regeneron Pharma Korlátozott immumglobulin könnyûlánc-repertoárt expresszáló egerek
PL2967012T3 (pl) 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
MY191512A (en) * 2013-09-18 2022-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
EP3233912B1 (en) 2014-12-19 2021-05-19 Regenesance B.V. Antibodies that bind human c6 and uses thereof
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
AU2016214399B2 (en) 2015-02-05 2020-01-16 Basf Se Solar power plant comprising a first heat transfer circuit and a second heat transfer circuit
CN107438622A (zh) * 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
EP3533867A4 (en) 2016-10-31 2020-07-22 National University Corporation Tottori University NON-HUMAN ANIMAL PRODUCING HUMAN ANTIBODIES AND PROCESS FOR THE PREPARATION OF HUMAN ANTIBODIES USING IT
EP4567119A3 (en) * 2016-11-04 2025-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
WO2019113065A1 (en) 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
JP7269963B2 (ja) 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP7594440B2 (ja) 2018-10-26 2024-12-04 ビークルエナジージャパン株式会社 電池制御装置
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
PT3979790T (pt) * 2019-06-05 2026-05-05 Regeneron Pharma Roedores possuindo um reportrio limitado de cadeias leves lambda expressadas a partir do lcus kappa e suas utilizaes
KR102953869B1 (ko) * 2019-07-01 2026-04-17 조에티스 서비시즈 엘엘씨 유전자이식 포유동물 및 이의 사용 방법
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021261620A1 (ko) * 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
WO2022130023A1 (en) 2020-12-14 2022-06-23 University Health Network Immunoglobulin light chain antibodies and uses thereof
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
AU2024265613A1 (en) 2023-05-04 2025-09-25 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026373A1 (en) 1998-11-03 2000-05-11 Babraham Institute MURINE EXPRESSION OF HUMAN Igμ LOCUS
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP1972194A1 (en) * 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
AU2002309063B8 (en) * 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
WO2008022391A1 (en) * 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
US8012714B2 (en) * 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
PL2346994T3 (pl) * 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
SG183149A1 (en) * 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
MY195217A (en) * 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026373A1 (en) 1998-11-03 2000-05-11 Babraham Institute MURINE EXPRESSION OF HUMAN Igμ LOCUS
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Exp Med. 1999 May 17; 189(10): 1611-1620.

Also Published As

Publication number Publication date
US9334333B2 (en) 2016-05-10
JP2020062061A (ja) 2020-04-23
KR102193823B1 (ko) 2020-12-22
KR20200064166A (ko) 2020-06-05
RS54891B1 (sr) 2016-10-31
US20150320023A1 (en) 2015-11-12
SI2905338T1 (sl) 2017-12-29
DK2905338T3 (da) 2017-11-06
US20130323790A1 (en) 2013-12-05
HRP20160865T1 (hr) 2016-10-07
SMT201900241T1 (it) 2019-05-10
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
US9850462B2 (en) 2017-12-26
ZA201404600B (en) 2015-09-30
ME02444B (me) 2016-09-20
US20150173332A1 (en) 2015-06-25
PL2480676T3 (pl) 2016-10-31
HRP20171666T1 (hr) 2017-12-15
IL300712B2 (en) 2024-11-01
IL223719A (en) 2016-10-31
EP2480676A1 (en) 2012-08-01
MX2022002117A (es) 2022-03-17
EP2905338B8 (en) 2018-01-24
CN103068994B (zh) 2016-01-20
IL282872A (en) 2021-06-30
NZ707200A (en) 2016-04-29
JP2018023403A (ja) 2018-02-15
DK3034608T3 (da) 2019-05-06
ES2576928T3 (es) 2016-07-12
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
HUE036597T2 (hu) 2018-07-30
US20160060359A1 (en) 2016-03-03
MY157477A (en) 2016-06-15
PT2480675T (pt) 2016-07-11
ME02440B (me) 2016-09-20
US9844212B2 (en) 2017-12-19
BR112012032991B1 (pt) 2021-08-10
KR101945352B1 (ko) 2019-02-07
ES2570131T3 (es) 2016-05-17
CY1117692T1 (el) 2017-05-17
CY1122877T1 (el) 2021-05-05
HRP20160794T1 (hr) 2016-08-12
KR101970944B1 (ko) 2019-04-23
US20190153384A1 (en) 2019-05-23
US9206261B2 (en) 2015-12-08
KR20130027555A (ko) 2013-03-15
PT2480676E (pt) 2016-06-09
EP2480676B1 (en) 2016-04-06
RU2601297C2 (ru) 2016-10-27
MY195214A (en) 2023-01-11
ME03386B (me) 2020-01-20
IL269078A (en) 2019-11-28
DK2568049T3 (en) 2016-08-01
HUE029692T2 (en) 2017-03-28
KR20190014578A (ko) 2019-02-12
HRP20160497T1 (hr) 2016-07-15
SMT201700506T1 (it) 2018-01-11
KR102001430B1 (ko) 2019-07-18
CN104404050B (zh) 2018-06-08
US20200239837A1 (en) 2020-07-30
MX348942B (es) 2017-07-04
HK1183321A1 (en) 2013-12-20
BR112012032991A8 (pt) 2020-09-29
JP6009441B2 (ja) 2016-10-19
TR201905992T4 (tr) 2019-05-21
JP2025027148A (ja) 2025-02-26
KR20190142436A (ko) 2019-12-26
IL244450A (en) 2017-11-30
SI2480675T1 (sl) 2016-08-31
EP3205726A1 (en) 2017-08-16
US20240327785A1 (en) 2024-10-03
MX347318B (es) 2017-04-21
DK2480675T3 (en) 2016-08-01
IL291301A (en) 2022-05-01
US20160057979A1 (en) 2016-03-03
KR102462042B1 (ko) 2022-11-03
KR20180135996A (ko) 2018-12-21
NZ605758A (en) 2014-08-29
US9066502B2 (en) 2015-06-30
IL300712A (en) 2023-04-01
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
NZ707198A (en) 2016-04-29
US20170107484A1 (en) 2017-04-20
US9540452B2 (en) 2017-01-10
US20120070861A1 (en) 2012-03-22
US9226484B2 (en) 2016-01-05
RU2724736C2 (ru) 2020-06-25
JP6073441B2 (ja) 2017-02-01
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
US9029628B2 (en) 2015-05-12
WO2011163314A1 (en) 2011-12-29
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
US9006511B2 (en) 2015-04-14
US20140137275A1 (en) 2014-05-15
KR102211911B1 (ko) 2021-02-05
SMT201600212B (it) 2016-08-31
ME02902B (me) 2018-04-20
JP2019033765A (ja) 2019-03-07
JP7236409B2 (ja) 2023-03-09
AU2011271043A1 (en) 2013-01-31
JP2018201528A (ja) 2018-12-27
SG186391A1 (en) 2013-01-30
MY195217A (en) 2023-01-11
HUE044001T2 (hu) 2019-09-30
RS55037B1 (sr) 2016-12-30
IL259965A (en) 2018-07-31
SG186390A1 (en) 2013-01-30
KR101934852B1 (ko) 2019-01-04
KR102506001B1 (ko) 2023-03-07
IL244450A0 (en) 2016-04-21
KR20190049932A (ko) 2019-05-09
RS55042B1 (sr) 2016-12-30
EP2480675B1 (en) 2016-04-06
US9163092B2 (en) 2015-10-20
ES2646052T3 (es) 2017-12-11
RU2590594C2 (ru) 2016-07-10
IL255179B (en) 2018-06-28
AU2011271043A9 (en) 2015-10-01
RU2013102596A (ru) 2014-07-27
JP2017012204A (ja) 2017-01-19
PL2568049T3 (pl) 2017-03-31
CN103068994A (zh) 2013-04-24
KR20230036157A (ko) 2023-03-14
US20150176002A1 (en) 2015-06-25
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
JP6545773B2 (ja) 2019-07-17
PT3034608T (pt) 2019-05-28
SMT201600229B (enExample) 2016-08-31
RU2013102595A (ru) 2014-07-27
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
ME02442B (me) 2016-09-20
CN104342455B (zh) 2017-05-31
KR20210013376A (ko) 2021-02-03
KR20200143511A (ko) 2020-12-23
CY1119478T1 (el) 2018-03-07
SG10201504568YA (en) 2015-07-30
HUE030285T2 (en) 2017-05-29
US20190203171A1 (en) 2019-07-04
ZA201404601B (en) 2016-02-24
BR112012033248A2 (pt) 2017-11-28
US9399683B2 (en) 2016-07-26
IL313063A (en) 2024-07-01
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
CA2804311C (en) 2017-09-12
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
JP6963542B2 (ja) 2021-11-10
NZ626979A (en) 2015-05-29
HK1170766A1 (zh) 2013-03-08
MY195212A (en) 2023-01-11
SG10201504324UA (en) 2015-07-30
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
IL291301B1 (en) 2023-03-01
SMT201600213B (it) 2016-08-31
US20150351371A1 (en) 2015-12-10
JP2016010417A (ja) 2016-01-21
SI2568049T1 (sl) 2016-10-28
CA2803864A1 (en) 2011-12-29
EP3034608A1 (en) 2016-06-22
IL259965B (en) 2019-02-28
IL247386A (en) 2017-07-31
EP3456832A1 (en) 2019-03-20
CN103068993A (zh) 2013-04-24
KR20220150430A (ko) 2022-11-10
MX336344B (es) 2016-01-15
PL2905338T3 (pl) 2018-01-31
JP2023133554A (ja) 2023-09-22
IL223720A (en) 2017-05-29
JP2016010415A (ja) 2016-01-21
RU2016119423A3 (enExample) 2019-11-19
JP2017006152A (ja) 2017-01-12
SI2480676T1 (sl) 2016-10-28
MX2012015300A (es) 2013-05-01
CY1118126T1 (el) 2017-06-28
US9150662B2 (en) 2015-10-06
JP5988969B2 (ja) 2016-09-07
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
KR101991234B1 (ko) 2019-06-20
IL291301B2 (en) 2023-07-01
HK1226766A1 (en) 2017-10-06
EP2568049B1 (en) 2016-04-13
US9394373B2 (en) 2016-07-19
US20150173331A1 (en) 2015-06-25
CA2803864C (en) 2017-05-16
CN103068993B (zh) 2016-01-06
PL3034608T3 (pl) 2019-08-30
LT2480675T (lt) 2016-10-10
CN104342455A (zh) 2015-02-11
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
ZA201300062B (en) 2014-09-25
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
US9035128B2 (en) 2015-05-19
JP2026066390A (ja) 2026-04-16
EP3034608B1 (en) 2019-01-30
JP2020128440A (ja) 2020-08-27
AU2011271043A8 (en) 2016-01-21
RS56589B1 (sr) 2018-02-28
US20150089680A1 (en) 2015-03-26
KR20190073584A (ko) 2019-06-26
ZA201506598B (en) 2017-03-29
CA2804311A1 (en) 2011-12-29
NZ627119A (en) 2015-05-29
MX347322B (es) 2017-04-21
US9012717B2 (en) 2015-04-21
JP2013531501A (ja) 2013-08-08
LT2905338T (lt) 2017-12-27
EP2568049A1 (en) 2013-03-13
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
US20150246976A1 (en) 2015-09-03
KR20210073609A (ko) 2021-06-18
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
AU2011271046A1 (en) 2013-01-31
NZ605751A (en) 2014-10-31
US20150246977A1 (en) 2015-09-03
EP2905338A1 (en) 2015-08-12
US20170258059A1 (en) 2017-09-14
MY165287A (en) 2018-03-21
US9206262B2 (en) 2015-12-08
CY1117537T1 (el) 2017-04-26
RS58736B1 (sr) 2019-06-28
IL255179A0 (en) 2017-12-31
KR20180135997A (ko) 2018-12-21
AU2011271046B2 (en) 2015-10-01
JP2021061863A (ja) 2021-04-22
HRP20190807T1 (hr) 2019-08-23
JP6341972B2 (ja) 2018-06-13
NO2905338T3 (enExample) 2017-12-30
CN104404050A (zh) 2015-03-11
KR102059909B1 (ko) 2019-12-27
HUE029691T2 (en) 2017-03-28
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
US20130326647A1 (en) 2013-12-05
MY194456A (en) 2022-11-30
IL300712B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
KR102059909B1 (ko) 사람 람다 가변 영역 및 마우스 불변 영역을 갖는 경쇄를 발현하는 마우스
KR102186822B1 (ko) 인간화 경쇄 마우스
RU2833566C2 (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРИАБЕЛЬНОЙ ОБЛАСТЬЮ λ ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190430

Application number text: 1020187036183

Filing date: 20181213

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190530

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190809

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200227

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200528

Application number text: 1020187036183

Filing date: 20181213

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200528

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200529

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240424

Start annual number: 5

End annual number: 5